Você procurou por: the study enrolled 75 patients (Inglês - Maltês)

the study enrolled 269 patients with cll.
l-istudju rreġistra fih 269 pazjent b’cll.

the study enrolled 145 adult and 21 paediatric patients.
l-istudju inkluda 145 adult u 21 pazjent pedjatriku.

study 020 enrolled
studju 020 kellu

study 301 enrolled patients who had received prior docetaxel.
studju 301 daħħal fih pazjenti li qabel kienu rċivew docetaxel.

the study enrolled patients who had not received prior therapy for their metastatic disease.
il-pazjenti rreġistrati fl-istudju ma kinux irċevew terapija minn qabel għall-marda metastatika tagħhom.

the study included 69 patients aged 6 years and above.
l-istudju kien jinkludi 69 pazjent minn 6 snin 'il fuq.

uncover-1 enrolled 1,296 patients.
uncover-1 irreġistra fih 1,296 pazjent.

one study in germany enrolled 38 late-onset patients with 36 months follow up.
fil-Ġermanja sar studju wieħed b’follow-up sa 36 xahar fejn kienu rreġistrati 38 pazjenti bil-marda ta’ pompe li bdiet tard fil-ħajja tagħhom

ahus study c10-004 enrolled 41 patients who displayed signs of thrombotic microangiopathy (tma).
studju ahus c10-004 kienu arwolati fih 41 pazjent li wrew sinjali ta’ mikroanġjopatija trombotika (tma).

eighteen patients completed the study.
tmintax-il pazjent temmew l-istudju.

the prevail study enrolled chemotherapy-naive patients; whereas the affirm study enrolled patients who had received prior docetaxel.
l-istudju prevail irreġistra pazjenti li qatt ma ħadu kimoterapija fil-passat, filwaqt li l-istudju affirm irreġistra pazjenti li rċivew docetaxel fil-passat.

two of the studies recruited patients who were
tnejn mill- istudji kienu

eighteen patients completed the study to week 48.
tmintax il-pazjent temmew l-istudju sa ġimgħa 48.

patients with secondary mds were excluded from the study.
pazjenti b’mds sekondarja kienu esklużi mill-istudju.

13 patients were enrolled.
13-il pazjent ġew irreġistrati.

two patients were re-treated twice in the study.
Żewġ pazjenti ġew trattati mill-ġdid darbtejn fl-istudju.

a total of 10 pah subjects enrolled and completed the study.
total ta’ 10 suġġetti bi pah ddaħħlu fl-istudju u lestewh.

patients who previously failed bosentan therapy were excluded from the study.
pazjenti li t-terapija b’bosentan ma ħadmitx fuqhom qabel, ġew esklużi minn dan l-istudju.

the study enrolled a total of 123 previously treated male patients (12 to 71 years of age) with severe haemophilia b (≤ 2% endogenous fix activity).
l-istudju rreġistra total ta’ 123 pazjent raġel li ġew ikkurati fil-passat (minn 12 sa 71 sena) b’emofilija b severa (≤2% ta’ attività fix endoġena).

11 patients were enrolled and 9 patients are on-going in the study.
11-il pazjent ġew irreġistrati u 9 pazjenti għadhom qed jipparteċipaw fl-istudju.